Comparative genomic hybridisation for the analysis of chromosomal imbalances in solid tumours and haematological malignancies.
Comparative genomic hybridisation (CGH) is based on a two-colour, competitive fluorescence in situ hybridisation of differentially labelled tumour and reference DNA to normal metaphase chromosomes. This new technology has made a great impact in molecular tumour pathology due to its possible application to archival specimens and the ability to create copy number karyotypes throughout the whole genome from very small amounts of DNA. If chromosomal imbalances can be correlated with a etiological and clinical features of tumours, CGH could be able to provide new prognostic and diagnostic criteria. CGH findings further provide starting points for the molecular genetic characterisation of altered chromosomal regions harbouring yet unidentified genes involved in tumorigenesis and tumour progression. An overview of the results of published CGH studies on solid tumours and haematological malignancies is presented. Methodological limitations of the CGH technology are reported, as well as future developments which will improve its use in routine analysis.
Zitzelsberger
H
H
GSF-Forschungszentrum für Umwelt und Gesundheit, Institut für Strahlenbiologie, Oberschleissheim, Germany. Zitzelsberger@gsf.de
Lehmann
L
L
Werner
M
M
Bauchinger
M
M
D002869:Chromosome Aberrations; D005544:Forecasting; D019337:Hematologic Neoplasms / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000295:instrumentation / Q000379:methods*; D009369:Neoplasms / Q000235:genetics*